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Tony Frew (1955-2018) was a leading member of the British Society 
for Allergy and Clinical Immunology and was well-respected in the 
European and US scientific community. Prof. Frew’s outstanding 
aptitudes are evident from his academic achievements, teaching 
and research careers, and leadership and impact on the European 
Academy of Allergy and Clinical Immunology (EAACI).
His scientific interest began at an early age as he excelled in 
knowledge and enthusiasm. He demonstrated his intellectual abil-
ities at the age of 13 when he won the prestigious scholarship to 
Westminster School. As a Queen’s Scholar, he was invited to observe 
Parliament and attend elite events at Westminster Abbey. At age 17, 
he won a maths scholarship to Peterhouse, University of Cambridge. 
His interest in mucosal immunology and T cells surfaced at the age 
of 22 as a medical student whilst working on a research project on 
coeliac disease.
He completed his doctoral thesis in Barry Kay’s laboratory at the 
National Heart & Lung Institute, London. His research focused on 
the immune pathology of the allergic reaction, particularly on the 
late-phase response, the emerging role of T cells and the interac-
tion between eosinophils and T cells. By examining the pattern of 
human late-phase skin reactions to extracts of aeroallergens, he was 
able to elucidate the differences between skin and lung responses 
to allergen exposure.1,2 The differences between allergen-induced 
late-phase reactions and delayed-type hypersensitivity were evalu-
ated.3 After defending his thesis in London, he moved to Vancouver, 
Canada, to pursue postdoctoral studies on occupational asthma. His 
PhD and postdoctoral work paved the way to an extraordinary sci-
entific career where he was completely committed to his students 
and patients in allergy and respiratory medicine.
In 1992, Tony Frew joined Stephen Holgate’s group at the 
University of Southampton School of Medicine where he was later 
appointed to a personal chair as full professor. In 2005, he and his 
family moved to Brighton where he helped establish the medical ed-
ucation program at the hospital. From an early stage in his career, 
Prof. Frew had a broad interest in research. His first clinical work 
focussed on the clinical and immunological features of western red 
cedar asthma,4 comparing this type of occupational asthma with pa-
tients having irritant-induced asthma.5 He considered occupational 
asthma as a good model to study the resolution of asthma in general. 
In later years, he extended his research to environmental exposures 
and contributed to a series of scientific papers on the effects of 
pollutants, such as ozone, nitrogen dioxide and diesel exhaust, on 
airway inflammation and sensitization to allergens. In an important 
study, he described the cytokine profile in asthmatic airways before 
and after local allergen challenge.6 In his research, he was never far 
away from the patient. His observations on the immune pathology 
of asthmatics are examples of what is currently broadly referred to 
as translational research.
His clinical research also evaluated the efficacy of allergen im-
munotherapy (AIT). He led randomized clinical trials on AIT with 
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grass pollen, house dust mite and cat epithelia. Notably, in 2006, 
he published a large multicentre dose-range finding trial of sub-
cutaneous grass pollen AIT among treatment-resistant patients 
that underlined the importance of AIT as a valuable treatment mo-
dality.7 Moreover, he coordinated and was involved in many Task 
Force (TF) initiatives with a special focus on methodological stan-
dards in AIT trial design. As such, Prof. Frew initiated an EAACI Task 
Force on placebo effects in AIT trials composed of international 
key-opinion leaders in this fascinating field. He is a senior author 
of a recently published EAACI TF Position Paper, “Placebo effects 
in allergen immunotherapy - an EAACI Task Force Position Paper”,8 
which is dedicated to his achievements for this initiative. Together 
with Helen Smith, his wife and professor of Family Practice and 
Primary Care, he wrote several papers on the practice of allergy 
care, especially in primary care.9 They demonstrated that in the UK 
a substantial part of hospital-based allergy care could be carried 
out by general practitioners (GPs), leaving the more complex cases 
to specialists.
Why was Tony special? His research encompassed the different 
elements of basic science, clinical studies, and the implementation 
of science into clinical practice, but there was more than that. He 
was also a great teacher and mentor. He gave numerous lectures in 
a bright, clear, and humorous manner. After moving to Brighton, one 
of his great achievements was the establishment of the new medical 
school at Brighton University. His house was always open for junior 
doctors working with him.
Above all, he remained a medical doctor, working at a respiratory 
medicine department whilst trying to balance his clinical duties with 
his academic research and international travels. He was loved and 
respected by his patients and co-workers.
Tony loved travelling, speaking with and learning from people 
from other countries, and studying other cultures. He spoke fluent 
German, French and Italian. In an interview, he describes his interests 
in European affairs to date back to the early 1970s when he worked 
as a hospital porter in Hamburg. This period was a starting point for a 
lifelong interest in Europe and in the development of its Central and 
Eastern regions. From that perspective, it is easy to understand that 
Tony developed into a tireless advocate for Allergology and Clinical 
Immunology in Europe, and particularly for EAACI, the scientific or-
ganization that stands for this field.
His involvement in EAACI started in 1989. He was appointed as 
Secretary to the subcommittee on skin tests and allergen standard-
ization. In 1995, he joined the Executive Committee (ExCom) of the 
EAACI and in 1999 became Secretary General. Under the leader-
ship of EAACI President Gunnar Johansson, new structures in the 
Academy were established, including interest groups and task force 
sections, where Tony was a leading figure. Years later, after assuming 
the position of President of EAACI in 2005, he was instrumental in 
establishing our current system of Vice-Presidents where they as-
sume different responsibilities, such as coordinating congresses and 
the dissemination of medical information. This was an essential step 
for shaping the Academy for the future.
Tony loved the work at EAACI. For him, the Summer and Winter 
Schools were marked by a combination of scientific collegiality and a 
sense of an academic family. He said that Europe is being seen more 
and more as an open place to receive attention for your work.
He witnessed the growth and success of the Academy through 
the years, a success that can be largely attributed to his efforts. 
Three years after his EAACI Presidency—as Chair of the 2010 EAACI 
Meeting in London—he could reap the benefits of the strong organi-
zation he helped forward and organized an EAACI Congress which 
became one of the largest allergy and immunology meetings held 
in Europe (Figure 1). He was recognized in 2011 with the Charles 
Blackley Award for promoting the specialty in Europe.
Tony remained committed to his “home society”, the British 
Society for Allergy and Clinical Immunology (BSACI), where he 
served as Council, Treasurer, Secretary, and President. In 2016, 
he received the William Frankland Award in recognition of his 
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outstanding contributions to British clinical allergy. The year after, 
he delivered the prestigious Jack Pepys Lecture at the BSACI Annual 
Meeting. Few people have received these two awards, Tony was one 
of them.
What makes Tony remarkable? A legend? It is not a specific 
achievement in his research, teaching, or medical career. It is the col-
lection of his many talents that made the inspirational man he was. 
In every way, he was a true European advocate of Allergology and 
Clinical Immunology.
In 2018, Tony passed away much too young at the age of 63. He 
is still missed.
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